2022 World Conference on Lung Cancer (ePosters)-EP16.03-043. Comprehensive Genomic Profiling of Tumor Mutational Burden-high in Chinese Lung Cancer Patients

EP16.03-043. Comprehensive Genomic Profiling of Tumor Mutational Burden-high in Chinese Lung Cancer Patients

Pdf Summary

A study was conducted to analyze the comprehensive genomic profiling of tumor mutational burden-high (TMB-H) in lung cancer patients in China. The understanding of TMB-H lung cancer in Chinese patients is still limited. TMB-H is an indication biomarker for pan-cancer immunotherapy approved by the FDA. The study retrospectively analyzed next-generation sequencing and clinicopathological data of 566 Chinese lung cancer tissue samples, including various pathological subtypes.<br /><br />The results showed that TMB-H was identified in 20.7% of patients, including cases of lung adenocarcinoma, lung squamous cell carcinoma, small cell lung cancer, and other types of lung cancer. The most recurrent mutant genes were TP53, LRP1B, CDKN2A, MLL2, PIK3CA, PTPRD, SOX2, MYC, KRAS, MLL3, EGFR, and RB1. It was also found that one TMB-H lung squamous cell carcinoma patient had a MSH2-EIF2C2 fusion, which requires further investigation.<br /><br />The study also revealed that TMB-H is relatively higher in male patients and can be seen in various pathological subtypes. TMB-H may coexist with gene mutations positively associated with immunotherapy and driver alterations negatively associated with immunotherapy. Further study should be conducted to explore potential immunotherapy strategies among the TMB-H population with lung cancer.<br /><br />In conclusion, this study provides insights into TMB-H in Chinese lung cancer patients and highlights the need for further research to understand the molecular and clinical characteristics of TMB-H lung cancer.

Asset Subtitle

Wei Li

Meta Tag

Speaker Wei Li

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

comprehensive genomic profiling

TMB-H

lung cancer patients

China

pan-cancer immunotherapy

next-generation sequencing

clinicopathological data

TP53

MSH2-EIF2C2 fusion

immunotherapy